Scientific Talks

Scientific Talks

Apr 27, 2016

Cognitive Computing and Big Data*

Michael Hehenberger, PhD, Partner, HM Nanomed LLC

The term ‘Cognitive Computing’ has been defined by IBM as ‘computing systems that learn and interact naturally with people to extend what either humans or machine could do on their own, and helping human experts make better decisions by penetrating the complexity of Big Data’. In 2005, Ray Kurzweil redefined ‘Singularity’,...

Read More
Apr 27, 2016

Creating Value With Big Data*

Bob Silverman, Operational Partner, Gilde Healthcare

The promise for using big data in the healthcare field is enormous. Our ability to capture tissue behavior, biomarker, genetic and genomic, information is extraordinary. At the same time the volume of medical data we collect is staggering where we now talk about quantity in terms of “yottabytes (1024 bytes). And,...

Read More
Apr 27, 2016

Road to Commercializing an Image Analysis-based Immuno-oncology Diagnostic*

Thomas Nifong, MD, Executive Vice President Predictive Tests, Definiens Inc.

Immunohistochemistry (IHC) is an essential technology for measuring biomarkers in cancer patients to determine prognosis and predict therapeutic responses. The interpretation of IHC is typically accomplished by manually scoring cells based on relative staining intensity, and calculating a semiquantitative score. Classic IHC-based biomarkers include ER, PR, Her2, and Ki-67 in breast...

Read More
Apr 27, 2016

Computational Pathology for Predicting Prostate Cancer Recurrence After Surgery*

Peter Gann, MD, Professor Department of Pathology, University of Illinois at Chicago College of Medicine

Background: Prostate cancers (PCa) are distinguished by wide variability in aggressiveness. While the Gleason grading system has provided a durable foundation for determining prognosis for 40 years, improved outcome prediction would benefit patients by identifying those in need of adjuvant therapy or more intensive monitoring. We are developing an approach...

Read More
Apr 27, 2016

Identifying Biomarkers for Companion Diagnostics in Immuno-oncology*

Marlon Rebelatto, PhD, Principal Pathologist, MedImmune LLC

The work in the last 30 years in immuno-oncology has clearly demonstrated that the immune system is capable of detecting and destroying cancerous cells. A better understanding of the immunological mechanisms involved in the immune response against tumor antigens has led to the development of effective immunotherapies, which are having...

Read More